Elite Pharma Inc (ELTP) 0.3250 $ELTP Increasing Demand

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Elite Pharma Inc (ELTP) 0.3250 $ELTP

Increasing Demand in Graphene 3-D Printing Technology Company: Graphene 3D Lab
ACCESSWIRE - Thu Mar 24, 7:32AM CDT
MIAMI, FL / ACCESSWIRE / March 24, 2016 / EmergingGrowth.com - Graphene 3D Lab (OTCQB: GPHBF) wholly owned subsidiary Graphene Laboratories, Inc. offers over 100 Graphene and related products to more than 10,000 customers worldwide including every Fortune 500 tech company and major research university.
NETE: 0.29 (+0.01), GS: 152.20 (+1.92), CLF: 3.53 (+0.48), HPQ: 12.13 (+0.07)

Penny Stocks to Buy on St. Patrick's Day... If You So Choose
ACCESSWIRE - Thu Mar 17, 10:54AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 17, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. HTBX, CLF, BTU, and ELTP have been added to our watchlist today. Continue reading to find out why. - To get daily alerts on top stocks on the OTCQB, OTCQX, Nasdaq, NYSE, and OTCBB, subscribe to our newsletter at DailyStockReporter.com.
HTBX: 0.57 (-0.03), BTU: 2.12 (unch), CLF: 3.53 (+0.48)

Elite Announces U.S. FDA Priority Review Designation for SequestOx(TM) NDA
GlobeNewswire - Thu Mar 17, 6:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced that the New Drug Application (NDA) for SequestOX(ELI-200), Elite's lead opioid abuse-deterrent candidate for the management of moderate to severe pain where the use of an opioid analgesic is appropriate, has been accepted and granted priority review by the United States Food and Drug Administration ("FDA". The FDA has set a target action date under the Prescription Drug User Fee Act ("PDUFA" of July 14, 2016.

What are Investors Looking at - Research on WorldFlix, Elite Pharmaceuticals, South32 and Koninklijke DSM
ACCESSWIRE - Tue Mar 08, 7:25AM CST
NEW YORK, NY / ACCESSWIRE / March 8, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: WorldFlix Inc. (OTC: WRFX), Elite Pharmaceuticals Inc. (OTC: ELTP), South32 Ltd. (OTC: SOUHY) and Koninklijke DSM NV (OTC: RDSMY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

$200 Million Order, Industrial Commodities Co. Strikes Gold in Iron Ore
ACCESSWIRE - Wed Feb 10, 7:31AM CST
MIAMI, FL / ACCESSWIRE / February 10, 2016 / $200 Million Order, Industrial Commodities Co. Strikes Gold in Iron Ore. CD International Enterprises, Inc. (OTCPK: CDII), a U.S.-based company that sources industrial commodities just announced that a $200 million order, over a 24-month period was placed with its wholly owned subsidiary Capital Resources Management Corporation.
CLF: 3.53 (+0.48)

Elite Pharmaceuticals generates higher consolidated revenues of USD2.2m for Q3 fiscal 2016
M2 - Wed Feb 10, 4:58AM CST
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) stated on Tuesday that it recorded consolidated revenues of USD2.2m for the quarter ended 31 December 2015, the third quarter of its 2016 fiscal year.

Elite Pharmaceuticals, Inc. Reports Strong Growth for Third Quarter of Fiscal Year 2016
GlobeNewswire - Tue Feb 09, 3:32PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP), announced results for the quarter ended December 31, 2015, the third quarter of its 2016 fiscal year.

Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 3rd Quarter 2016 Financial Results on February 10, 2016
GlobeNewswire - Fri Feb 05, 11:43AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that its third quarter financial results will be released on Tuesday, February 9, 2016. Following the announcement, Elite's management will host a live conference call on Wednesday, February 10 at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update. Company executives will conduct a question and answer session following their remarks. Shareholders may submit questions for management in advance of the call.

Evaluating the Technicals - Research Reports on Trans-Pacific Aerospace Company, Medical Marijuana, Elite Pharmaceuticals, and Endonovo Therapeutics
ACCESSWIRE - Tue Feb 02, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / February 2, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Trans-Pacific Aerospace Company Inc. (OTC: TPAC), Medical Marijuana Inc. (OTC: MJNA), Elite Pharmaceuticals Inc. (OTC: ELTP) and Ekso Bionics Holdings Inc. (OTC: EKSO). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

Analyst Insights Behind Price Movement - Analyst Research on CD International Enterprises, Elite Pharmaceuticals, Anglo American and Pilot Gold
ACCESSWIRE - Mon Feb 01, 7:25AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CD International Enterprises Inc. (OTC: CDII), Elite Pharmaceuticals Inc. (OTC: ELTP), Anglo American PLC (OTC: NGLOY) and Pilot Gold Inc. (OTC: PLGTF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

Traders Look to Upside - Analyst Research on SandRidge Energy, Elite Pharmaceuticals, Dyadic International and Accretive Health
ACCESSWIRE - Thu Jan 21, 8:34AM CST
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SandRidge Energy Inc. (OTC: SDOC), Elite Pharmaceuticals Inc. (OTC: ELTP), Dyadic International Inc. (OTC: DYAI) and Accretive Health Inc. (OTC: ACHI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
SD: 0.15 (-0.02)

Elite Pharmaceuticals awarded waiver fee for ELI-200 NDA under section 736(d)(1)(E) of the Federal Food, Drug and Cosmetic Act
M2 - Fri Jan 15, 5:10AM CST
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) stated on Thursday that it has received a waiver of the application fee required for the filing of a New Drug Application (NDA) for ELI-200 from the US Food and Drug Administration (FDA).

Today's Market Driven by Key Factors - New Research on Trans-Pacific Aerospace Company, Elite Pharmaceuticals, First Mining Finance and Golden Queen Mining
ACCESSWIRE - Thu Jan 14, 7:30AM CST
NEW YORK, NY / ACCESSWIRE / January 14, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Trans-Pacific Aerospace Company Inc. (OTC: TPAC), Elite Pharmaceuticals Inc. (OTC: ELTP), First Mining Finance Corp. (OTC: FFMGF) and Golden Queen Mining Co. Ltd. (OTC: GQMNF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

Elite Pharmaceuticals reports changes in board
M2 - Thu Jan 14, 6:27AM CST
Elite Pharmaceuticals (OTCBB:ELTP) said on Wednesday that Jerry Treppel has stepped down as its chairman and as a member of the board of directors with effect from 11 January 2016, to pursue other opportunities.

FDA Approves Waiver of NDA Filing Fee for Elite Pharmaceuticals
GlobeNewswire - Wed Jan 13, 3:52PM CST
The United State Food and Drug Administration ("FDA" granted Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) a waiver of the application fee required for the filing of a New Drug Application (NDA). Under section 736(d)(1)(E) of the Federal Food, Drug and Cosmetic Act the FDA may grant a waiver of the $2,335,200 NDA application fee for the first human drug application that a small business submits for review.

Nasrat Hakim Named Chairman of Board of Directors for Elite Pharmaceuticals
GlobeNewswire - Wed Jan 13, 8:25AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced that Jerry Treppel has resigned as the Company's Chairman and as a member of the Board of Directors, effective January 11, 2016, to pursue other opportunities.

Five Small Cap Stocks Experiencing Huge Growth Potential
ACCESSWIRE - Fri Dec 11, 7:18AM CST
DELRAY BEACH, FL / ACCESSWIRE / December 11, 2015 / In today's quickly evolving market, small cap stocks increasingly profile as a viable investment for those with a higher risk tolerance. While the global market stirs, newer, smaller companies continue to claim larger portions of industry shares, and surprising names begin to surface as possible leaders in their respective fields.

Equity Market Movement at a Glance - Research on Northwest Biotherapeutics, Elite Pharmaceuticals, Ekso Bionics Holdings, and Medical Marijuana
ACCESSWIRE - Tue Nov 24, 7:10AM CST
NEW YORK, NY / ACCESSWIRE / November 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Northwest Biotherapeutics Inc. (NASDAQ: NWBO),Elite Pharmaceuticals Inc. (OTC: ELTP), Ekso Bionics Holdings Inc. (OTC: EKSO) and Medical Marijuana Inc. (OTC: MJNA). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 1.62 (-0.04)

The Price Data Tells the Story - Research on Northwest Biotherapeutics, Elite Pharmaceuticals, Barrett Business Services and Ekso Bionics Holdings
ACCESSWIRE - Mon Nov 16, 7:02AM CST
NEW YORK, NY ACCESSWIRE / November 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Northwest Biotherapeutics Inc (NASDAQ: NWBO),Elite Pharmaceuticals Inc (OTC: ELTP), Barrett Business Services Inc (NASDAQ: BBSI) and Ekso Bionics Holdings Inc (OTC: EKSO). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 1.62 (-0.04), BBSI: 27.55 (+0.32)

Direction of Market Influences - Research on PositiveID, Elite Pharmaceuticals, Century Communities and Innerworkings
ACCESSWIRE - Thu Nov 12, 7:25AM CST
NEW YORK, NY / ACCESSWIRE / November 12, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: PositiveID Corp (OTC: PSID), Elite Pharmaceuticals Inc (OTC: ELTP), Century Communities Inc (NYSE: CCS) and Innerworkings Inc (NASDAQ: INWK). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CCS: 17.72 (+0.35), INWK: 7.93 (-0.07)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 308

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 501

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 595

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 18

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 45

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Initiated for Voyager Therapeutics Investors

Updated Category News Views 115

Investigation Overview for Voyager Therapeutics Investors Pomerantz LLP is currently exploring possible claims on behalf of investors in Voyager Therapeutics, Inc. (NASDAQ: VYGR). This exploration arises from concerns surrounding the company’s recent announcements and operational strategies. Details of the Investigation The inquiry focuses on whether Voyager and some of...

Continue Reading
Subway's Creative Middle Seat Reward for Travelers

Updated Category News Views 132

Subway Announces Exciting Promotion for Air Travelers On January 27, a significant change is happening for travelers, especially for those who dread sitting in the middle seat of a plane. With a popular airline ending its open seating policy, millions are gearing up for assigned seating. This means that many passengers might find themselves in the middle seat, which is...

Continue Reading
Expanse Studios Unveils Innovative Games at Major Summit

Updated Category News Views 86

Expanse Studios Shines at Industry Summit Expanse Studios, a cutting-edge gaming developer and a subsidiary of Golden Matrix Group Inc. (NASDAQ: GMGI), has made a significant impression at the recent SBC Summit Lisbon. This event attracted around 25,000 attendees, featuring a mix of gaming innovators and industry experts, all eager to explore what's next in the gaming...

Continue Reading
Unlocking Digital Preservation Skills Through New Academy

Updated Category News Views 150

Introducing the Preservica Academy for Digital Preservation Preservica Inc. has unveiled its exciting new initiative, Preservica Academy, dedicated to enhancing the skills of professionals and beginners in the realm of digital preservation. This innovative program focuses on Active Digital Preservation™, aiming to ensure the long-term accessibility and integrity of...

Continue Reading
Seritage Growth Properties Investors Alert: Class Action Lawsuit Update

Updated Category News Views 107

Notification of Class Action Lawsuit for Seritage Growth Properties Levi & Korsinsky, LLP is reaching out to inform investors of Seritage Growth Properties (NYSE: SRG) regarding an ongoing class action securities lawsuit. This case marks an important development for those affected by alleged securities fraud. Overview of the Class Action Lawsuit This lawsuit is centered...

Continue Reading